已发表论文

代谢组学:一个有前景的乳腺癌诊断和治疗工具

 

Authors Chen Z, Li Z, Li H, Jiang Y

Received 14 May 2019

Accepted for publication 22 July 2019

Published 21 August 2019 Volume 2019:12 Pages 6797—6811

DOI https://doi.org/10.2147/OTT.S215628

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Rachel Predeepa

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

Abstract: Breast cancer (BC) is the most commonly diagnosed cancer among women and the leading cause of cancer death. Despite the advent of numerous diagnosis and treatment methods in recent years, this heterogeneous disease still presents great challenges in early diagnosis, curative treatments and prognosis monitoring. Thus, finding promising early diagnostic biomarkers and therapeutic targets and approaches is meaningful. Metabolomics, which focuses on the analysis of metabolites that change during metabolism, can reveal even a subtle abnormal change in an individual. In recent decades, the exploration of cancer-related metabolomics has increased. Metabolites can be promising biomarkers for the screening, response evaluation and prognosis of BC. In this review, we summarized the workflow of metabolomics, described metabolite signatures based on molecular subtype as well as reclassification and then discussed the application of metabolomics in the early diagnosis, monitoring and prognosis of BC to offer new insights for clinicians in breast cancer diagnosis and treatment.
Keywords: diagnosis, biomarkers, treatment, metabolites



Table 1 Molecular subtypes of BC based on metabolomics